Antibodies are used for preventing several infectious diseases in food animals. Though, antibiotics can deal with infection however, their widespread usage may cause developments of resistance and can also get transferred to humans through animal products. Therefore, production of antibodies against infectious agents in the egg yolk could be an interesting alternative. The present study was conducted with a focus on producing the antibody against Escherichia coli E68 and H28 in egg yolk of laying hens, which are believed to be a cause for diarrhea and beriberi in piglets. The result received from the experiment were promising and have shown efficiency of antibody production in the range of 2-7.3% in the groups which are infected with E68 only and the one which was infected with both strains. The outcome of present research has revealed the potentiality of egg yolk in production of antibody for laying hens, could open a new approach for production of antibodies to manage diarrhea and beriberi

Mesenchymal stem cells (MSCs) are considered to be attractive approaching in gene or drug delivery for cancer therapeutic strategies. In this study, the ability and feasibility of human bone marrow derived MSCs expressing the cytosine deaminase (CD)/5-Fluorocytosin (5-FC) prodrug was evaluated to target human osteosarcoma cell line Cal-72. At first, the fibroblast-like cells were successfully obtained from human bone marrow and demonstrated that they contained full of stem characteristics by the ability of differentiation into adipocyte/osteocyte and expression of typical mesenchymal markers CD90, CD44, while negative for CD34 and CD133 markers. We established the stable CD-expressing MSCs cell line (CD-MSCs) by transfection of pEGFP-C3 containing cytosine deaminase::uracil phos-phoribosyltransferase (CD::UPRT) gene into MSCs, and confirmed that the manipulated MSCs still remained full characteristics of multipotent cells and shown migration toward human osteosarcoma cancer cells Cal-72 as high as origin MSCs. Based on bystander effect, the therapeutic CD-MSCs significantly augmented the cytotoxicity on cancer cell Cal72 in either direct co-culture or conditioned medium in the presence of 5-FC. Moreover, in osteosarcoma cancer- bearing mice, the therapeutic CD/5-FC MSCs showed the inhibition of tumor growth compared with control mice which was s.c injected with only Cal72. Our findings suggest that these therapeutic CD-MSCs may be suitable and viable cellular vehicles for targeting human osteosarcoma cancer.